Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

768 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Antibody-Drug Conjugates in Breast Cancer: What Is Beyond HER2?
Nicolò E, Repetto M, Boscolo Bielo L, Tarantino P, Curigliano G. Nicolò E, et al. Among authors: curigliano g. Cancer J. 2022 Nov-Dec 01;28(6):436-445. doi: 10.1097/PPO.0000000000000629. Cancer J. 2022. PMID: 36383906 Review.
Evaluation of triple negative breast cancer with heterogeneous immune infiltration.
Quintana Á, Arenas EJ, Bernadó C, Navarro JF, González J, Esteve-Codina A, Moliné T, Marti M, Curigliano G, Schmid P, Peg V, Arribas J, Cortés J. Quintana Á, et al. Among authors: curigliano g. Front Immunol. 2023 May 4;14:1149747. doi: 10.3389/fimmu.2023.1149747. eCollection 2023. Front Immunol. 2023. PMID: 37215143 Free PMC article.
Think "HER2" different: integrative diagnostic approaches for HER2-low breast cancer.
Marchiò C, Criscitiello C, Scatena C, Santinelli A, Graziano P, Malapelle U, Cursano G, Venetis K, Fanelli GN, Pepe F, Berrino E, Angelis C, Perrone G, Curigliano G, Fusco N. Marchiò C, et al. Among authors: curigliano g. Pathologica. 2023 Dec;115(6):292-301. doi: 10.32074/1591-951X-942. Pathologica. 2023. PMID: 38180137 Free PMC article. Review.
How I treat endocrine-dependent metastatic breast cancer.
Gombos A, Goncalves A, Curigliano G, Bartsch R, Kyte JA, Ignatiadis M, Awada A. Gombos A, et al. Among authors: curigliano g. ESMO Open. 2023 Apr;8(2):100882. doi: 10.1016/j.esmoop.2023.100882. Epub 2023 Feb 17. ESMO Open. 2023. PMID: 36806375 Free PMC article. Review.
Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021.
Burstein HJ, Curigliano G, Thürlimann B, Weber WP, Poortmans P, Regan MM, Senn HJ, Winer EP, Gnant M; Panelists of the St Gallen Consensus Conference. Burstein HJ, et al. Among authors: curigliano g. Ann Oncol. 2021 Oct;32(10):1216-1235. doi: 10.1016/j.annonc.2021.06.023. Epub 2021 Jul 6. Ann Oncol. 2021. PMID: 34242744 Free PMC article. Review.
Unlocking the Potential: Biomarkers of Response to Antibody-Drug Conjugates.
Ascione L, Guidi L, Prakash A, Trapani D, LoRusso P, Lou E, Curigliano G. Ascione L, et al. Among authors: curigliano g. Am Soc Clin Oncol Educ Book. 2024 Jun 1;44(3):e431766. doi: 10.1200/EDBK_431766. Am Soc Clin Oncol Educ Book. 2024. PMID: 38828973 Free article. Review.
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial.
Cortés J, Hurvitz SA, Im SA, Iwata H, Curigliano G, Kim SB, Chiu JWY, Pedrini JL, Li W, Yonemori K, Bianchini G, Loi S, Borges GS, Wang X, Bachelot T, Nakatani S, Ashfaque S, Liang Z, Egorov A, Hamilton E. Cortés J, et al. Among authors: curigliano g. Nat Med. 2024 Jun 2. doi: 10.1038/s41591-024-03021-7. Online ahead of print. Nat Med. 2024. PMID: 38825627
Deleterious alterations in homologous recombination repair genes and efficacy of platinum-based chemotherapy in biliary tract cancers.
Belli C, Boscolo Bielo L, Repetto M, Crimini E, Scalia R, Diana A, Orefice J, Ascione L, Pellizzari G, Fusco N, Barberis M, Daniele B, Guerini-Rocco E, Curigliano G. Belli C, et al. Among authors: curigliano g. Oncologist. 2024 Jun 1:oyae125. doi: 10.1093/oncolo/oyae125. Online ahead of print. Oncologist. 2024. PMID: 38823036 Free article.
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-Breast03 trial.
Hurvitz SA, Kim SB, Chung WP, Im SA, Park YH, Hegg R, Kim MH, Tseng LM, Petry V, Chung CF, Iwata H, Hamilton E, Curigliano G, Xu B, Egorov A, Liu Y, Cathcart J, Bako E, Tecson K, Verma S, Cortés J. Hurvitz SA, et al. Among authors: curigliano g. ESMO Open. 2024 May;9(5):102924. doi: 10.1016/j.esmoop.2024.102924. Epub 2024 Apr 24. ESMO Open. 2024. PMID: 38796287 Free PMC article. Clinical Trial.
768 results